Does a small molecule cardiac myosin activator improve cardiac function in systolic heart failure?
Cardiac myosin activation via a small molecule represents a potential therapeutic approach to improve cardiac function in systolic heart failure.
A small molecule improves cardiac function by accelerating the transition of myosin into a force-producing state.
Malik et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: